Skip to main content
. 2022 Jul;23(7):2317–2323. doi: 10.31557/APJCP.2022.23.7.2317

Figure 2.

Figure 2

Comparison of Progression-Free Survival between RT with Concurrent and adjuvant Temozolomide (arm 1) and RT alone (arm 2)